Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

The prognostic value of elevated ezrin in patients with osteosarcoma

Authors: Deng-Xing Lun, Yong-Cheng Hu, Zhao-Wan Xu, Li-Na Xu, Bin-Wu Wang

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Published studies researching the prognostic significance of ezrin expression in patients with osteosarcoma are inconclusive and heterogeneous. We conducted a meta-analysis to assess its prognostic value more precisely. The hazard ratios with corresponding 95 % confidence intervals were calculated to evaluate the effects. Five studies with 318 osteosarcoma patients were included to estimate the relationship between ezrin and disease-free survival, and ezrin and overall survival. Compared with osteosarcoma patients with low or negative ezrin expression, patients with high ezrin expression tended to be associated with lower disease-free survival, but the difference was not significant. However, patients with high ezrin expression were obviously associated with lower overall survival. Therefore, the findings from this systematic review suggest that ezrin expression is an effective biomarker of prognosis in patients with osteosarcoma.
Literature
1.
2.
Niswander LM, Kim SY. Stratifying osteosarcoma: minimizing and maximizing therapy. Curr Oncol Rep. 2010;12:266–70.PubMedCrossRef
3.
Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, et al. Palliative therapy for osteosarcoma. Expert Rev Anticancer Ther. 2011;11:217–27.PubMedCrossRef
4.
Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586–99.PubMedCrossRef
5.
Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M. Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell. 2003;14:2181–91.PubMedCentralPubMedCrossRef
6.
Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 2006;23:227–36.PubMedCrossRef
7.
Kanamori M, Sano A, Yasuda T, Hori T, Suzuki K. Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors. J Exp Clin Cancer Res. 2012;31:100.PubMedCrossRef
8.
Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef
9.
10.
11.
Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-Analysis. PLoS One. 2013;8:e69366.PubMedCentralPubMedCrossRef
12.
Kim MS, Song WS, Cho WH, Lee SY, Jeon DG. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res. 2007;459:229–36.PubMedCrossRef
13.
Salas S, Bartoli C, Deville JL, Gaudart J, Fina F, Calisti A, et al. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch. 2007;451:999–1007.PubMedCrossRef
14.
Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr Blood Cancer. 2008;50:752–6.PubMedCrossRef
15.
16.
Boldrini E, Peres SV, Morini S, de Camargo B. Immunoexpression of ezrin and CD44 in patients with osteosarcoma. J Pediatr Hematol Oncol. 2010;32:e213–7.PubMedCrossRef
17.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
18.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
19.
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
20.
Chen X, Tian HM, Yu XJ. Bone delivers its energy information to fat and islets through osteocalcin. Orthop Surg. 2012;4(2):114–7.PubMedCrossRef
21.
Dunn J, Dunn C, Habbu R, Bohay D, Anderson J. Effect of pregnancy and obesity on arch of foot. Orthop Surg. 2012;4(2):101–4.PubMedCrossRef
22.
Wang LJ, Yang HL, Shi YX, Jiang WM, Chen L. Pulmonary cement embolism associated with percutaneous vertebroplasty or kyphoplasty: a systematic review. Orthop Surg. 2012;4(3):182–9.PubMedCrossRef
23.
Malhotra P, Anwar M, Nanda N, Kochhar R, Wig JD, Vaiphei K, et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumor Biol. 2013;34:1901–11.CrossRef
24.
Krifa M, Alhosin M, Muller CD, Gies JP, Chekir-Ghedira L, Ghedira K, et al. Limoniastrum guyonianum aqueous gall extract induces apoptosis in human cervical cancer cells involving p16 INK4A re-expression related to UHRF1 and DNMT1 down-regulation. J Exp Clin Cancer Res. 2013;32:30.PubMedCrossRef
25.
Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegård J, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol. 2013;34:1013–20.CrossRef
26.
27.
Adamo R, Comandini A, Aquino A, Bonmassar L, Guglielmi L, Bonmassar E, et al. The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro. J Exp Clin Cancer Res. 2013;32:38.PubMedCrossRef
28.
Zhang H, Qi C, Li L, Luo F, Xu Y. Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res. 2013;32:56.PubMedCrossRef
29.
Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281–6.PubMedCrossRef
30.
Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374–8.PubMedCrossRef
31.
Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–72.PubMedCrossRef
Metadata
Title
The prognostic value of elevated ezrin in patients with osteosarcoma
Authors
Deng-Xing Lun
Yong-Cheng Hu
Zhao-Wan Xu
Li-Na Xu
Bin-Wu Wang
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1168-2

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis

Research Article

Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis

Research Article

Inhibition of focal adhesion kinase induces apoptosis in human osteosarcoma SAOS-2 cells

Research Article

XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis

Research Article

Antitumor activity of a sulfated polysaccharide from Enteromorpha intestinalis targeted against hepatoma through mitochondrial pathway

Research Article

Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits